Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

The Top Gene-Sequencing Stock to Buy in 2017

By Brian Orelli, PhD - Apr 20, 2017 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Illumina is investors' best buy in this category.

Investors have fairly limited options for buying gene-sequencing companies -- there just aren't that many to invest in. And some of the companies involved in gene sequencing aren't exclusively focused on it.

But one company stands out: Illumina.

Company

Instruments

2016 Revenue From Gene Sequencing

Fraction of Sales From Gene Sequencing

Illumina ( ILMN -2.10% )

MiniSeq, MiSeq, NextSeq, HiSeq, NovaSeq

$2.0 billion

84%

Pacific Biosciences of California ( PACB -8.92% )

Sequel

$91 million

100%

Qiagen ( QGEN -1.67% )

GeneReader

N/D

N/D

Thermo Fisher Scientific ( TMO -1.06% )

Ion Torrent

N/D

N/D

Data source: Company press releases and 10-Ks. N/D=not disclosed.

Qiagen and Thermo Fisher Scientific both have quite a few other products for clinical and research labs that have nothing to do with gene sequencing. Investors looking to specifically take advantage of the growth potential of gene sequencing should look elsewhere simply because their growth will be limited by Qiagen's and Thermo Fisher Scientific's other products.

Two-horse race

That leaves Pacific Biosciences and Illumina, whose machines sequence DNA in completely different ways. Pacific Biosciences' single molecule, real-time (SMRT) technology produces long reads while Illumina's technology involves breaking up the DNA into small fragments that are then sequenced.

Breaking up the DNA limits the applications that Illumina's machines are capable of. The short sequences have to be lined up to a known sequence, so sequencing new organisms would be very hard to do. The short sequences also make it hard to interpret regions of the genomes that repeat since it isn't clear where that fragment came from.

Nevertheless, Illumina is the leader in sales by an order of magnitude for one reason: price. Illumina has brought the price of sequencing a human genome down to $1,000, and the company thinks its newest machine, the NovaSeq, can bring the cost down to $100 with technological advances over the next few years.

Pacific Biosciences will be able to fill the niches where Illumina's machines don't perform well, but researchers will migrate to Illumina's machines for applications where its machines are capable -- which would include most human genome studies that make up a large percent of the future market -- simply because it's cheaper to use Illumina's machines.

NovaSeq 6000

NovaSeq 6000. Image source: Illumina.

The biggest risk

As with any technology company, there's always the possibility that a competitor could develop a way to sequence DNA faster or cheaper, but I think Illumina's biggest risk is its own success. As the price of sequencing gets to a reasonable level and the usefulness of the data increases as more genetic changes are linked to diseases and other traits -- how patients respond to medication, for instance -- everyone's doctor will order whole genome sequencing.

And then what?

For the most part, most people will only need to get their genomes sequenced once, leading to sales eventually being tied to the birth rate. That transition is years away, but Illumina is already making moves to deal with the eventual slowdown in sales of sequencing machines and reagents.

While patients might only have their genomes sequenced once, it's likely that doctors will want to look at that data multiple times over the life of the patient, so Illumina has spunoff a company called Helix that's developing a store where developers can sell apps to analyze the DNA sequence while Helix takes a percentage of the developers' sales.

And through another spinoff called GRAIL, Illumina is looking to use its machines to screen for tumor DNA in blood samples. GRAIL recently announced a 120,000-person study to validate its method screening for breast cancer in women. Having a screening tool for cancer could potentially boost sales substantially because, unlike sequencing, patients would be screened multiple times over their lifetimes.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$357.66 (-2.10%) $-7.67
Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$21.14 (-8.92%) $-2.07
Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$626.15 (-1.06%) $-6.68
QIAGEN N.V. Stock Quote
QIAGEN N.V.
QGEN
$54.21 (-1.67%) $0.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.